SiBone (NASDAQ:SIBN – Get Free Report) and Nexalin Technology (NASDAQ:NXL – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.
Volatility & Risk
SiBone has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.08, indicating that its share price is 308% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for SiBone and Nexalin Technology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SiBone | 1 | 0 | 6 | 0 | 2.71 |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
Profitability
This table compares SiBone and Nexalin Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SiBone | -6.85% | -8.23% | -6.07% |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
Valuation & Earnings
This table compares SiBone and Nexalin Technology”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SiBone | $200.93 million | 4.34 | -$18.90 million | ($0.34) | -57.88 |
| Nexalin Technology | $300,000.00 | 6.42 | -$8.22 million | ($14.41) | -0.18 |
Nexalin Technology has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
98.1% of SiBone shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
SiBone beats Nexalin Technology on 9 of the 14 factors compared between the two stocks.
About SiBone
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
